Evidence map›Paper›PMID 37568406›Full record

ReviewJournal of clinical medicine2023

Comparative Analysis of Morbidity and Mortality Outcomes in Elderly and Nonelderly Patients Undergoing Elective TEVAR: A Systematic Review and Meta-Analysis.

Angelos Frisiras, Emmanuel Giannas, Stergios Bobotis, Ilektra Kanella, Arian Arjomandi Rad, Alessandro Viviano, Kyriakos Spiliopoulos, Dimitrios E Magouliotis, Thanos Athanasiou

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Angelos FrisirasFaculty of Medicine, Imperial College London, Charing Cross Hospital, London W6 8RF, UK.
Emmanuel GiannasFaculty of Medicine, Imperial College London, Charing Cross Hospital, London W6 8RF, UK.
Stergios BobotisFaculty of Medicine, Imperial College London, Charing Cross Hospital, London W6 8RF, UK.
Ilektra KanellaFaculty of Medicine, Imperial College London, Charing Cross Hospital, London W6 8RF, UK.
Arian Arjomandi RadMedical Sciences Division, University of Oxford, Oxford OX1 3AZ, UK.ORCID 0000-0002-4931-4049
Alessandro VivianoDepartment of Cardiothoracic Surgery, Imperial College NHS Trust, Hammersmith Hospital, London W12 0HS, UK.
Kyriakos SpiliopoulosDepartment of Cardiothoracic Surgery, University of Thessaly, Biopolis, 41 110 Larissa, Greece.
Dimitrios E MagouliotisUnit of Quality Improvement, Department of Cardiothoracic Surgery, University of Thessaly, Biopolis, 41 110 Larissa, Greece.ORCID 0000-0001-5417-6392
Thanos AthanasiouDepartment of Surgery and Cancer, Imperial College London, St Mary's Hospital, London W2 1NY, UK.
Charing Cross Hospital · GBUniversity of Thessaly · GRHammersmith Hospital · GBSt Mary's Hospital · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDue to an ever-increasing ageing population and limited available data around the use of thoracic endovascular aortic repair (TEVAR) in elderly patients, investigating its efficacy and safety in this age cohort is of vital importance. We thus reviewed the existing literature on this topic to assess the feasibility of TEVAR in elderly patients with severe thoracic aortic pathologies.

methodsWe identified all original research studies that assessed TEVAR in elderly patients published up to 2023. Morbidity, as assessed by neurological and respiratory complications, endoleaks, and length of stay, was the primary endpoint. Short-term mortality and long-term survival were the secondary endpoints. The Mantel-Haenszel random and fixed effects methods were used to calculate the odds ratios for each outcome. Further sensitivity and subgroup analyses were performed to validate the outcomes.

resultsTwelve original studies that evaluated elective TEVAR outcomes in elderly patients were identified. Seven studies directly compared the use of TEVAR between an older and a younger patient group. Apart from a shorter hospital stay in older patients, no statistically significant difference between the morbidity outcomes of the two different cohorts was found. Short-term mortality and long-term survival results favoured the younger population.

conclusionsThe present meta-analysis indicates that, due to a safe perioperative morbidity profile, TEVAR should not be contraindicated in patients based purely on old age. Further research using large patient registries to validate our findings in elderly patients with specific aortic pathologies and both elective and emergency procedures is necessary.

Indexed as

ageelderlyendovascular repairmorbiditymortalityTEVARthoracic aorta

Identifiers

PMID37568406
PMCPMC10420243
OpenAlexW4385421080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.